BJU International最新文献

{"title":"A novel comprehensive cancer genome profiling for non‐metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease","authors":"Maria Chiara Sighinolfi, Giuseppe Pallotta, Simone Assumma, Enrico Panio, Francesco Pinto, Filippo Gavi, Angelo Totaro, Simona Presutti, Tina Pasciuto, Camilla Nero, Marzia del Re, Luca Tagliaferri, Chiara Ciccarese, Roberto Iacovelli, Antonio Gabarrini, Ela Patel, Marcio Covas Moschovas, Vipul Patel, Bernardo Rocco","doi":"10.1111/bju.70019","DOIUrl":"https://doi.org/10.1111/bju.70019","url":null,"abstract":"Background and ObjectiveProstate cancer (PCa) presents with substantial biological heterogeneity and variable clinical outcomes. While genomic alterations in high‐risk and locally advanced cases may signal early progression or micrometastatic disease, their clinical finding and utility remains underexplored. This study aims to apply a comprehensive cancer genome profiling through next‐generation sequencing (NGS) to identify actionable mutations predictive of disease progression in non‐metastatic PCa.Study DesignThis single‐centre, prospective observational cohort study (<jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">ClinicalTrials.gov</jats:ext-link>: NCT06875297) is designed to recruit patients with high‐risk or locally advanced PCa undergoing radical prostatectomy (RP); a complementary arm of low‐risk patients managed by either active surveillance or RP are considered as well. Participants are enrolled from the Fondazione Policlinico Universitario A. Gemelli IRCCS.EndpointsThe primary endpoint is to detect Association for Molecular Pathology (AMP)‐American Society of Clinical Oncology [ASCO]‐College of American Pathologists [CAP] Tier I–II genomic alterations associated with biochemical recurrence or progression in high‐risk and locally advanced PCa. Secondary endpoints include genomic alterations relevant to time to radiographic progression and castration resistance; for the low‐risk subset, upstage and/or upgrade are considered as actionable endpoints to be predicted through NGS.Funding and Ethics and Trial RegistrationThe study is non‐profit, ethically approved (Lazio Area 3, identifier: 7618), and registered at <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">ClinicalTrials.gov</jats:ext-link> (NCT06875297).","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"90 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflatable penile prosthesis implantation performed by residents after a structured training pathway","authors":"Liliana Guadagni, Marco Falcone","doi":"10.1111/bju.70028","DOIUrl":"https://doi.org/10.1111/bju.70028","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"28 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145261023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient‐reported outcome measures in prostate research: a scoping review","authors":"Grace J. Young, Eleanor I. Walsh, J. Athene Lane, Jenny L. Donovan, Marcus J. Drake, Hugo Pedder, Chris Metcalfe","doi":"10.1111/bju.70022","DOIUrl":"https://doi.org/10.1111/bju.70022","url":null,"abstract":"ObjectivesTo summarise how patient‐reported outcome measures (PROMs) are used in prostate research, specifically in the 10 years after the 2010 CONsolidated Standards Of Reporting Trials (CONSORT) guidelines were introduced.MethodsThe search was focussed on randomised controlled trials (RCTs) reporting in the top 15 journals in oncology, urology, and medicine, during 2011–2020 and identified through PubMed®. For each article the following items were identified: the condition being treated, the intervention(s) of interest, the study design, the specific PROM(s) used, when they were included in the treatment pathway, how they were analysed, and whether methods to deal with multiplicity or missing data were considered.ResultsThere were 361 potentially eligible articles identified from the PubMed search, of which 121 were eligible for the full‐text review. The articles were RCTs assessing interventions for lower urinary tract symptoms (<jats:italic>n</jats:italic> = 54) or prostate cancer (<jats:italic>n</jats:italic> = 67), for which the most commonly reported PROMs were the International Prostate Symptom Score (50/54) and Functional Assessment of Cancer/Chronic Illness Therapy questionnaires (28/67), respectively. Details on the analysis and handling of PROMs were difficult to obtain; notably, 60% of articles failed to mention whether any methods had been used for dealing with multiplicity or missing data. An incidental finding was that sexually inactive men were excluded from analyses in some of the articles.ConclusionsOur scoping review highlights the need to refine the way PROMs are incorporated and analysed in prostate randomised trials, so their findings can be efficiently applied in further research and clinical practice. Adherence to the CONSORT guidelines, specifically clear reporting of the timing of PROMs, the handling of missing data, and multiplicity, should be encouraged. RCTs in prostate cancer would benefit from core outcome and measurement sets, to avoid unnecessary overlap and facilitate evidence synthesis.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"6 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scribe smarter, not harder: how artificial intelligence scribes stack up against human clinicians","authors":"Alice Thomson, Marlon Perera, Declan Murphy, Nathan Lawrentschuk","doi":"10.1111/bju.70037","DOIUrl":"https://doi.org/10.1111/bju.70037","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"22 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse in-hospital outcomes in patients with paraplegia who undergo radical prostatectomy.","authors":"Andrea Marmiroli,Francesco Di Bello,Natali Rodriguez Peñaranda,Mattia Longoni,Quynh Chi Le,Fabian Falkenbach,Michele Nicolazzini,Calogero Catanzaro,Zhe Tian,Jordan A Goyal,Stefano Luzzago,Francesco Alessandro Mistretta,Mattia Piccinelli,Fred Saad,Shahrokh F Shariat,Alberto Briganti,Felix K H Chun,Salvatore Micali,Nicola Longo,Markus Graefen,Carlotta Palumbo,Riccardo Schiavina,Gennaro Musi,Pierre I Karakiewicz","doi":"10.1111/bju.70021","DOIUrl":"https://doi.org/10.1111/bju.70021","url":null,"abstract":"OBJECTIVETo test for the association between paraplegia and perioperative complications as well as in-hospital mortality after radical prostatectomy (RP) for non-metastatic prostate cancer.PATIENTS AND METHODSWe identified patients who underwent RP (National Inpatient Sample [NIS] 2000-2019), stratified according to paraplegia status. The NIS is an inpatient database that rests on data contributed by ~20% of community hospitals within the United States. Descriptive analyses, propensity score matching (PSM, ratio 1:10), and multivariable logistic regression models (LRMs) were used.RESULTSOf 260 302 patients who underwent RP, there were 223 (0.1%) with paraplegia. The patients with paraplegia who underwent RP were younger (age 60 vs 62 years; P = 0.002) and more frequently had Charlson Comorbidity Index ≥3 (46% vs 2.2%; P < 0.001). After 1:10 PSM, 223/223 (100%) patients with paraplegia and 2230/260 079 (0.9%) without paraplegia who underwent RP were included in further analyses. In multivariable LRMs, patients with paraplegia who underwent RP exhibited significantly higher in-hospital mortality (adjusted odds ratio [aOR] 10.7), higher rates of wound complications (aOR 8.2), infectious complications (aOR 6.2), genitourinary complications (aOR 3.5), intraoperative complications (aOR 2.8), cardiac complications (aOR 2.8), pulmonary complications (aOR 2.6), overall complications (aOR 2.4), blood transfusions (aOR 1.8), and longer length of stay ≥75th percentile (aOR 1.7) (all P ≤ 0.01).CONCLUSIONAlthough patients with paraplegia who undergo RP are rare, adverse in-hospital outcomes are substantially more frequent in these individuals. These observations should be carefully considered in clinical decision making and informed consent prior to RP, if such procedure is contemplated in patients with paraplegia.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"67 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical familiarity: many questions but the benefits are clear","authors":"Imogen A. Roberts, James W. F. Catto","doi":"10.1111/bju.70031","DOIUrl":"https://doi.org/10.1111/bju.70031","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"108 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer: medium-term outcomes and learning curve insights.","authors":"Alessandro Marquis,Michael J Schwartz,Alexandre Armache,Kenneth Solosky,Ravleen Kaur,Cynthia J Knauer,Scott Thompson,Samuel W Coons,Peter A Pinto,Ardeshir R Rastinehad","doi":"10.1111/bju.70014","DOIUrl":"https://doi.org/10.1111/bju.70014","url":null,"abstract":"OBJECTIVESTo assess the oncological and functional outcomes of magnetic resonance imaging-ultrasonography (MRI-US) fusion-guided focal cryoablation (FC) using a novel three-dimensional Advanced Annotation Platform (AAP) in patients with localised prostate cancer (PCa) and compare results between expert and beginner surgeons to evaluate the impact of prior focal therapy (FT) experience on FT outcomes.PATIENTS AND METHODSA prospective single-arm trial enrolled 50 men with low- to intermediate-risk PCa who underwent FC between December 2020 and September 2023. MRI-US fusion-guided FC was performed using the UroNav AAP by two surgeons with different FT experience (>200 vs 0), with 19 cases carried out by an expert and 31 by a beginner surgeon. Follow-up included prostate-specific antigen, multiparametric MRI, and protocol biopsy at 1 year. The primary outcome was failure-free survival (FFS), defined as the transition to radical salvage treatment or to systemic therapy, development of PCa metastases, or PCa-specific death. Secondary outcomes included oncological control and functional outcomes. Post hoc analyses were performed to assess learning curves and compare outcomes between surgeons with different experience levels.RESULTSThe 2-year FFS was 96% (95% confidence interval [CI] 90.7-100%). The 1-year protocol biopsy showed a 6% in-field (IFR) and 12% out-of-field recurrence (OFR) rates. Urinary function fully recovered at 3 months. Among men with baseline Sexual Health Inventory for Men score ≥17, 85% recovered erectile function at 1 year, with baseline function as the main predictor of recovery at 1 year. All complications (26%) were Common Terminology Criteria for Adverse Events Grade 1-2. There was no significant difference in FC outcomes between surgeons. Learning curves were demonstrated primarily for ablation time with a decrease of 1.44 min per case (95% CI -1.98 to -0.90), with small effects for number of cryoprobes (0.041 decrease per case, 95% CI -0.067 to -0.014) and OFR rate (0.014 decrease per case, 95% CI -0.028 to -0.0003), but not for the IFR rate and complications. No differences in learning patterns were observed between surgeons.CONCLUSIONFusion-guided FC using the UroNav AAP demonstrated good oncological control and safety profile. The device allowed precise MRI-US fusion-guided treatment while minimising the learning curve difference between expert and beginner surgeons.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"114 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancer","authors":"Reuben Ben‐David, Ahmed Eraky, Brenda Hug, Matthew D. Galsky, Che‐Kai Tsao, Kyrollis Attalla, Peter Wiklund, Reza Mehrazin, John P. Sfakianos","doi":"10.1111/bju.16926","DOIUrl":"https://doi.org/10.1111/bju.16926","url":null,"abstract":"ObjectivesTo investigate whether circulating tumour DNA (ctDNA) predicts oncological outcomes in the minimal residual disease (MRD) window after radical orchiectomy or retroperitoneal lymph node dissection (RPLND), and to evaluate the diagnostic performance of ctDNA in reference to imaging studies in clinical stage (CS) I disease.MethodsLongitudinal tumour‐informed ctDNA assays (Signatera™) were collected prospectively from consecutive patients during 2022–2023. The ctDNA signature was informed from the orchiectomy or RPLND specimen. The MRD window was defined as the initial 90 days after orchiectomy or RPLND. Event‐free survival (EFS) and recurrence‐free survival (RFS) were assessed using the Kaplan–Meier method.ResultsSixty patients with a median (interquartile range) follow‐up of 18 (13–23) months underwent 287 ctDNA analyses; 45% had seminoma. At initial staging, 65% had CS (clinical stage) I, 20% CS II, 3.3% CS III, and 10% CS IS. Post‐orchiectomy ctDNA clearance was achieved in 80% of patients, and patients with undetectable MRD ctDNA had superior 3‐month (100% vs 25% [95% confidence interval [CI] 7.5–83]) and 12‐month EFS (91% [95% CI 79–100] vs (13% [95% CI 2–78]) compared to detectable ctDNA, respectively. Undetectable MRD window ctDNA in patients with CS I undergoing surveillance was associated with an 18‐month RFS of 88%. The diagnostic performance of ctDNA compared to imaging studies for CS I per patient was: sensitivity 33.3%, specificity 93.5%, positive predictive value 33.3%, and negative predictive value (NPV) 93.5%. Detectable pre‐RPLND ctDNA fully correlated with tumour presence, while undetectable ctDNA corresponded to benign histology or teratoma on pathology. Undetectable RPLND MRD ctDNA was associated with superior 9‐month RFS vs detectable ctDNA (100% vs 25% [95% CI 5–100], respectively).ConclusionctDNA status in the MRD window predicted survival outcomes after orchiectomy and RPLND. Undetectable MRD window ctDNA demonstrated high NPV relative to imaging studies in CS I disease. Further investigation is warranted.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"79 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro”","authors":"","doi":"10.1111/bju.70026","DOIUrl":"https://doi.org/10.1111/bju.70026","url":null,"abstract":"<p>Palma Rocchi, Paul Jugpal, Alan So, Shannon Sinneman, Susan Ettinger, Ladan Fazli, Colleen Nelson and Martin Gleave. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. <i>BJU Int</i> 2006;97(6):1300–8. doi: https://doi.org/10.1111/j.1464-410X.2006.06425.x.</p>\u0000<p>In figure 2 of the “Results” section, the authors used blots that were previously published and did not mention the journal references. The authors would like to add previously published paper references.</p>\u0000<div>The authors apologize for these mistakes. The authors confirm that all the experimental results and corresponding conclusions mentioned in the paper remain unaffected. The corrected Figure 2 is shown as follows. <figure>\u0000<div><picture>\u0000<source media=\"(min-width: 1650px)\" srcset=\"/cms/asset/b8789c67-7b1e-4558-9315-e3d9e681c5bd/bju70026-gra-0001-m.jpg\"/><img alt=\"image\" data-lg-src=\"/cms/asset/b8789c67-7b1e-4558-9315-e3d9e681c5bd/bju70026-gra-0001-m.jpg\" loading=\"lazy\" src=\"/cms/asset/b09ac4c4-97ea-416a-861f-fcb4a5a36591/bju70026-gra-0001-m.png\" title=\"image\"/></picture><p></p>\u0000</div>\u0000</figure>\u0000</div>\u0000<p>Adapted from previously published: Rocchi, P., <i>Cancer Research</i>, 2004;64(18):6595–602; Rocchi, P., <i>Cancer Research</i>, 2005;65(23):11083–93.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"16 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An endovascular approach for renal cell carcinoma with tumour thrombus: first urological case series","authors":"Darius Ashrafi, Bridget Heijkoop, Sean Ong, Jeremy Saad, Jason Toniolo, Laurencia Villalba, Minh Tran, Rahul Rindani","doi":"10.1111/bju.70033","DOIUrl":"https://doi.org/10.1111/bju.70033","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"197 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}